Navigation Links
Derma Sciences Reports Fourth Quarter Year-End Results for 2007

PRINCETON, N.J., April 1, 2008 /PRNewswire-FirstCall/ -- Derma Sciences Inc (OTC Bulletin Board: DSCI), a provider of advanced wound care products, reported that sales for 2007 were $34.1 million, an increase of 22 percent over the $27.9 million reported for 2006. Gross margins held steady at 34 percent, but due primarily to the costs of bringing in new products for the pipeline, and expanding the Company's marketing and sales staffs, the Company reported a loss of $2.3 million or $0.09 loss per share, versus a year-earlier profit or $668,739 or $0.03 per share.

Chairman and CEO Ed Quilty commented, "We believe it is important to note that sales increased significantly even though we did not launch the expanded sales force until late in the year. With world-class manufacturing in North America and China, a strong reputation for quality, some of the largest hospital suppliers in the world as customers, and proprietary wound care technologies that are unarguably the most distinctive in the industry -- Derma Sciences is in the right place at the right time."

The Company's 2007 loss included $653,012 of non-cash equity based compensation as compared to $211,756 in 2006, and $256,628 in connection with the early payoff of a credit facility during 2007. It also included $993,069 in research and development expenses, including a license fee charge of $868,069 for DSC127, a novel wound care product under development, versus none in 2006. The sales force was increased from two salespersons to nine; a national sales director was hired, as was a director of clinical affairs. Overall, general and administrative expenses increased from $4.8 million in 2006 to $6.2 million in 2007.

Subsequent Event

On March 31, 2008, the Company entered into securities purchase agreements with several accredited existing and new investors in connection with a private placement of common stock and warrants. Under the terms of the agreement, Derma will receive $6.1 million in gross proceeds from the sale of 6.1 million shares of its common stock and approximately 3.1 million warrants with an exercise price of $1.20. Subject to the satisfaction of customary closing conditions, the transaction is expected to close on or about April 2, 2008. Net proceeds from the transaction will be used to expand the sales force and marketing expenses, to potentially expand its license agreement with the Company's MEDIHONEY partner Comvita and for working capital and general corporate purposes. Pending such uses, the proceeds are expected to temporarily pay down the Company's existing revolving credit facility. The offering was conducted in reliance on Section 4(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. Oppenheimer & Co. Inc. acted as advisors and placement agent for the Company.

Conference Call / Webcast

Today at 11:00am EDT (8:00am PDT), a conference call will be held to review the DSCI results; interested parties should call 800-510-0219 (domestic) or 617-614-3451 (international), with passcode 77274977 to access the call. You may also access this call via the Internet at:

For those who are unavailable to listen to the live broadcast, a replay will be available through April 8, 2008 and can be accessed by dialing 888-286-8010 (domestic), and 617-801-6888 (international). The passcode is 71798685.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound- care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey- based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of two positive large-scale randomized controlled studies on leg ulcers. For more information about Derma Sciences, Inc., visit its home page on the Internet at

Forward-looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements Include but are not limited to, those discussed in the Company's filings with the Securities and Exchange Commission.




Consolidated Statements of Operations (Unaudited)

Three months ended

December 31,

2007 2006

Net Sales $10,651,944 $7,687,009

Cost of sales 7,231,758 5,041,739

Gross Profit 3,420,186 2,645,270

Operating expenses

Selling, general and administrative 3,968,259 2,399,899

Research and development 868,069 -

Goodwill impairment - 200,000

Total operating expenses 4,836,328 2,599,899

Operating (loss) income (1,416,142) 45,371

Other expense (income)

Interest expense 270,605 75,379

Loss on debt extinguishment 256,628 -

Other expense (income) 35,699 (21,950)

Total other expense 562,932 53,429

Loss before provision for income taxes (1,979,074) (8,058)

Provision for income taxes 66,869 99,341

Net Loss $(2,045,943) $(107,399)

Loss per common share - basic and diluted $(0.07) $0.00

Shares used in computing loss per common share

- basic and diluted 30,289,386 24,906,160

Consolidated Statements of Operations (Audited)

Year ended

December 31,

2007 2006

Net Sales $34,135,401 $27,887,391

Cost of sales 22,530,986 18,235,003

Gross Profit 11,604,415 9,652,388

Operating expenses

Selling, general and administrative 11,885,368 8,339,227

Research and development 993,069 -

Goodwill impairment - 200,000

Total operating expenses 12,878,437 8,539,227

Operating (loss) income (1,274,022) 1,113,161

Other expense (income)

Interest expense 413,992 374,079

Loss on debt extinguishment 256,628 -

Other expense (income) 77,929 (47,998)

Total other expense 748,549 326,081

(Loss) income before provision for income taxes (2,022,571) 787,080

Provision for income taxes 262,034 118,341

Net (Loss) Income $(2,284,605) $668,739

(Loss) income per common share - basic and

diluted $(0.09) $0.03

Shares used in computing (loss) income per

common share - basic 26,523,541 20,591,085

Shares used in computing (loss) income per

common share - diluted 26,523,541 24,409,760

SOURCE Derma Sciences Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
2. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
3. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
4. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
5. Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema
6. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
7. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
8. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
9. AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skins Natural Antioxidant System
10. Lucid Launches VivaNet(R) Telemedicine Server for Dermatology Applications
11. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
Post Your Comments:
(Date:4/27/2017)... ... April 27, 2017 , ... Oncolinx, a spin-out of the ... has truly taken their cancer research out of this world. On April 22, ... Canaveral to the International Space Station’s (ISS) U.S. National Laboratory, managed by the ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... Summit ( ) is coming to San Diego, CA on September 27-28, ... to learn about the latest advances in the treatment of various types of ...
(Date:4/27/2017)... ... April 27, 2017 , ... Volunteers supported by ... researchers, engineers, and industry professionals in visiting U.S. Congressional offices in Washington, D.C., ... the world photonics industry. , This year, National Photonics Initiative (NPI) ...
(Date:4/26/2017)... DIEGO, CALIF. (PRWEB) , ... April 26, 2017 ... ... Day? Lajollacooks4u, San Diego’s premiere team-building and cooking events company, offers one-of-a-kind ... classes. , Menus specialize in California cuisine, and guests leave inspired with ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):